Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin/Rosuvastatin Monolayer vs Bilayer Bioequivalence Study
NCT03867942Phase 1Unknown
- Sponsor
- LG Chem
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of gemigliptin and rosuvastatin in type 2 diabetes mellitus (T2DM) and dyslipidemia (2 arms), sponsored by LG Chem. Primary endpoints: Area Under the Curve for Gemigliptin at 72 hours, Area Under the Curve for Rosuvastatin at 72 hours and 2 more. Status: unknown.
02
Drugs
gemigliptinrosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT03867942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867942.